Pharmacists in Lynnfield, MA Accepting Medicare

4 Pharmacists found. Showing 1 - 4

Margot Bloom, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3 Windsor Rd, Lynnfield, MA 01940 Phone: 781-799-5422

Jay Fregeau, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 6 Jordan Rd, Lynnfield, MA 01940 Phone: 781-730-8716

Mr. Walter J Ciampa Jr., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Friendship Ln, Lynnfield, MA 01940 Phone: 978-406-1192

Debra Ambrefe Haraden, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 590 Main St, Lynnfield, MA 01940 Phone: 781-334-3133

News Archive

Tau biomarker could lead to early identification of Alzheimer's disease pathology

A discovery of high relevance in medical research will be published in Volume 55, number 4 of December 2016 of the prestigious "Journal of Alzheimer's Disease (JAD)", entitled "Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease".

Online health record safeguards may not be as secure as consumers hope

Almost a decade after a new law went into effect to strengthen health privacy protections, the number of breaches of patient records and databases across the U.S. suggests that personal health information is not as private or secure as many consumers might want or expect.

Keto diet may cause skin problems

Researchers from Austria have found that ketogenic diets could affect psoriasis-like skin inflammation in mice. They noted that keto diets including medium-chain triglycerides (MCTs) such as coconut along with omega-3 fatty acids obtained from nuts and seeds and fish oil could be a recipe for psoriasis exacerbation. They speculated that this could be true for humans as well. The study titled, "The Influence of Ketogenic Diets on Psoriasiform-Like Skin Inflammation," was published this week in the Journal of Investigative Dermatology.

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.

Read more Medical News

› Verified 6 days ago